Navigation Links
K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants
Date:8/3/2010

adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Note 20 – "Subsequent Events" of the Notes to the Consolidated Financial Statements in the Form 10-Q;
  • changes in the current and future business environment, including interest rates and capital and consumer spending;
  • the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized;
  • the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals, including with respect to Gestiva™, as well as the number of preterm births for which Gestiva™ may be prescribed, its safety profile and side effects profile;
  • acceptance of and demand for the Company's new pharmaceutical products or current products upon their return to the marketplace;
  • the introduction and impact of competitive products and pricing, including as a result of so-called authorized generic drugs;
  • new product development and launch, including the possibility that any product launch may be delayed;
  • reliance on key strategic acquisitions;
  • the availability of raw materials and/or products manufactured for the Company under contract manufacturing agreements with third parties;
  • the regulatory environment, including regulatory agency and judicial actions and changes in applicable laws or regulations;
  • fluctuations in revenues;
  • the difficulty of predicting international regulatory approvals, including timing;
  • the difficulty of predicting the pattern of inventory movements by the Company's customers;
  • the impact of competitive response to the Company's sales, marketing and strategic efforts, including introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries;
  • risks that the Company may not ultimately prevail in litigation, including product li
    '/>"/>

  • SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
    2. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    3. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
    4. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
    5. China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
    6. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
    7. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
    8. Viscira Delivers Key Presentation to Pharmaceutical Marketing Professionals at Leading Digital Industry Conference
    9. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
    10. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
    11. Angiotech Pharmaceuticals Announces Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)... SEOUL, South Korea , March 4, 2015 /PRNewswire/ ... based biopesticide company, in August of last year. As ... with Kyung Bon Koo continuing his role ... Selakovic , President of Vegalab S.A., will work alongside ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 ...
    (Date:3/3/2015)... DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... the quarter and seventh-month period ended December 31, 2014. ... its fiscal year end from May 31 to December ... we are reporting today are for the quarter and ...
    (Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) ... Market, 2015 - 2025" report to their offering. ... provides an extensive study on the marketed and pipeline ... out in this field for over a decade but ... Asian markets; one approved in the EU). There are ...
    (Date:3/3/2015)... (PRWEB) March 03, 2015 Crown Bioscience, ... company, has launched a new Life Science division specializing ... preclinical research. , The first products released include ... controls, and soon to be released in vivo grade ... continue to expand their life science portfolio with additional ...
    Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2
    ... has closed a public offering of three million ... million for general corporate purposes. , ,The company announced ... $3.75 per share, marketed to institutional investors following a ... Exchange Commission . , ,Sonic Foundry, which develops a ...
    ... , a Grand Rapids-based provider of data bandwidth capacity, will ... in metropolitan Milwaukee. , ,The company, which serves Midwestern enterprise ... 31 of this year. , ,US Signal's network deployment ... Milwaukee and powered by the Cisco optical platform. ...
    ... Madison, Wis. - Third Wave Technologies, Inc ., ... to the U.S. Food and Drug Administration for approval of ... test product, which Third Wave calls InPlex, is a genotyping ... to aid in newborn screening and in diagnostic testing in ...
    Cached Biology Technology:
    (Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
    (Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
    (Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
    Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
    ... of choice when it comes to the types of fat cells in ... it. The danger in white fat cells, along with the increased risk ... fat. Visceral fat is the build-up of fat around the organs in ... fat appears to be our friend and white fat our foe. ...
    ... FL (May 6, 2012) There may be new ... medicine injected directly into the eyes fails to cause ... called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle ... with the fast-progressive form of macular degeneration, they are ...
    ... in German . Halle/Saale. In order to ... These differ in part considerably from the propagation strategies of ... Knapp of the Helmholtz Centre for Environmental Research (UFZ) reached ... of the scientific journal Ecology Letters . "These results ...
    Cached Biology News:A new candidate pathway for treating visceral obesity 2First oral agent to quell invasive macular degeneration, restore lost vision 2First oral agent to quell invasive macular degeneration, restore lost vision 3Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3
    ...
    High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
    ... offers single pass sequencing of plasmids ... fueled by our high performance sequencing ... Phred20 bases per day. The key ... sequencing customers are rapid turnaround, high ...
    ... Agencourt offers a high quality whole genome ... while reducing costs allow even the smallest ... endeavors. The key features which set our ... unique library construction strategies, proprietary assembly software, ...
    Biology Products: